Abstract
RAD51 is essential for homologous recombination (HR)-mediated repair of DNA double-strand breaks (DSBs) in mammalian cells. RAD51 is an attractive target for anticancer drugs, given high RAD51 levels are frequently observed in many human tumors and associated with increased resistance to DSBs-inducing chemotherapeutics. Prodigiosin is a bacterial tripyrrole pigment with potent anticancer activity and also provokes DSBs. We hereby aimed to elucidate the role of RAD51 in prodigiosin-induced cytotoxicity. Prodigiosin was found to down-regulate RAD51 in multiple human breast carcinoma cell lines irrespective of p53 status. Mechanistically, prodigiosin lowered RAD51 mRNA expression, whereas blockade of proteasome-mediated degradation failed to restore RAD51 levels following prodigiosin treatment. In addition, prodigiosin triggered phosphorylation of JNK and p38 MAPK, while pharmacological inhibition of JNK or p38 MAPK attenuated prodigiosin-mediated inhibition of RAD51 mRNA expression. Lastly, cells with enforced RAD51 expression showed increased resistance to prodigiosin-induced cytotoxicity as well as inhibition of colony formation. Collectively, we conclude that RAD51 down-regulation represents one of the modes of prodigiosin's c...Continue Reading
References
Mar 25, 2005·Toxicological Sciences : an Official Journal of the Society of Toxicology·Beatriz MontanerRicardo Pérez-Tomás
Dec 3, 2005·EMBO Reports·Carmen Arias-LopezAugusto Silva
Jul 21, 2006·Cancer Letters·Ranju RalhanLisa Wiesmüller
Jan 24, 2007·Molecular Cancer Therapeutics·Vanessa Soto-CerratoRicardo Pérez-Tomás
Feb 13, 2007·Cancer Cell·Tom Walsh, Mary-Claire King
Sep 4, 2007·Biochemical Pharmacology·Vanessa Soto-CerratoRicardo Pérez-Tomás
Sep 21, 2007·Toxicology and Applied Pharmacology·Tsing-Fen HoChia-Che Chang
Apr 3, 2008·Cancer Research·Grazia AmbrosiniGary K Schwartz
May 14, 2008·Anti-cancer Agents in Medicinal Chemistry·Simon N Powell, Lisa A Kachnic
Jun 12, 2008·Carcinogenesis·Jen-Chung KoYun-Wei Lin
Nov 13, 2008·Molecular Cancer Therapeutics·Jen-Chung KoYun-Wei Lin
Jan 10, 2009·Toxicology and Applied Pharmacology·Tsing-Fen HoChia-Che Chang
Mar 12, 2009·Current Pharmaceutical Design·R PandeyK B Sainis
Jun 10, 2009·Experimental Cell Research·Ruey-Shyang ChenYun-Wei Lin
Oct 6, 2009·Biochemical Pharmacology·Jen-Chung KoYun-Wei Lin
Nov 28, 2009·Nucleic Acids Research·David Schild, Claudia Wiese
May 13, 2010·Current Medicinal Chemistry·R Pérez-Tomás, M Viñas
Sep 22, 2010·The Journal of Pharmacology and Experimental Therapeutics·Min-Shao TsaiYun-Wei Lin
Feb 1, 2011·Journal of Bioscience and Bioengineering·Chia-Che ChangYu-Hong Wei
Aug 4, 2011·Toxicology and Applied Pharmacology·Jen-Chung KoYun-Wei Lin
Dec 14, 2011·Biochemical Pharmacology·M Espona-FiedlerR Pérez-Tomás
Mar 1, 2012·British Journal of Pharmacology·Hsin-Ying HsiehChia-Che Chang
Citations
Feb 25, 2014·Applied Microbiology and Biotechnology·Nada StankovicJasmina Nikodinovic-Runic
Mar 6, 2013·PloS One·Ali HosseiniVictor Guallar
Sep 18, 2012·Toxicology and Applied Pharmacology·Mu-Yun PanChia-Che Chang
Feb 15, 2014·Toxicology Letters·Hongguang LianXianghong Zhang
Aug 16, 2016·Microbiology·Rita E MonsonGeorge P C Salmond
Oct 5, 2018·Journal of Clinical Medicine·Wei-Jun ChiuChing-Feng Weng
Mar 4, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mina RyuChangJu Chun
Aug 11, 2016·Oncotarget·Adrian P WiegmansAndreas Möller
Nov 8, 2018·International Journal of Molecular Sciences·Dan LiKai Zhao
Nov 7, 2019·International Journal of Molecular Sciences·Kai ZhaoXiujun Fan
Jun 13, 2020·Frontiers in Bioengineering and Biotechnology·Ivan GuryanovRawil Fakhrullin
Apr 8, 2020·Indian Journal of Microbiology·J C L LapendaS C Nascimento
Jun 18, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·San-Lang WangAnh Dzung Nguyen
Feb 2, 2019·Frontiers in Oncology·Jo-Fan ChangJih-Hwa Guh
Nov 4, 2020·Planta medica·Diego V WilkeLeticia V Costa-Lotufo